Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 85

1.

Small Private Online Course in Teaching Oncology-Feedback After 1 Year: What Lessons?

Vaysse C, Fize AL, Despas F, Chantalat E, Serrano E, Beyne-Rauzy O, Rougé-Bugat ME.

J Cancer Educ. 2019 Aug 13. doi: 10.1007/s13187-019-01598-z. [Epub ahead of print]

PMID:
31410821
2.

Impact of red blood cell transfusion dose density on progression-free survival in lower-risk myelodysplastic syndromes patients.

de Swart L, Crouch S, Hoeks M, Smith A, Langemeijer S, Fenaux P, Symeonidis A, Čermák J, Hellström-Lindberg E, Stauder R, Sanz G, Mittelman M, Holm MS, Malcovati L, Mądry K, Germing U, Tatic A, Savic A, Almeida AM, Gredelj-Šimec N, Guerci-Bresler A, Beyne-Rauzy O, Culligan D, Kotsianidis I, Itzykson R, van Marrewijk C, Blijlevens N, Bowen D, de Witte T; EUMDS Registry Participants.

Haematologica. 2019 Jun 6. pii: haematol.2018.212217. doi: 10.3324/haematol.2018.212217. [Epub ahead of print]

3.

[Management of myelodysplastic syndromes in 2019: An update].

Comont T, Delavigne K, Cougoul P, Bertoli S, Delabesse E, Fenaux P, Beyne-Rauzy O.

Rev Med Interne. 2019 Sep;40(9):581-589. doi: 10.1016/j.revmed.2019.04.001. Epub 2019 May 1. French.

PMID:
31054780
4.

A phase II study of guadecitabine in higher-risk myelodysplastic syndrome and low blast count acute myeloid leukemia after azacitidine failure.

Sébert M, Renneville A, Bally C, Peterlin P, Beyne-Rauzy O, Legros L, Gourin MP, Sanhes L, Wattel E, Gyan E, Park S, Stamatoullas A, Banos A, Laribi K, Jueliger S, Bevan L, Chermat F, Sapena R, Nibourel O, Chaffaut C, Chevret S, Preudhomme C, Adès L, Fenaux P; Groupe Francophone des Myélodysplasies (GFM).

Haematologica. 2019 Aug;104(8):1565-1571. doi: 10.3324/haematol.2018.207118. Epub 2019 Feb 7.

5.

Immune checkpoint inhibitor-related acral vasculitis.

Comont T, Sibaud V, Mourey L, Cougoul P, Beyne-Rauzy O.

J Immunother Cancer. 2018 Nov 16;6(1):120. doi: 10.1186/s40425-018-0443-6.

6.

Risk factors for bleeding, including platelet count threshold, in newly diagnosed immune thrombocytopenia adults.

Piel-Julian ML, Mahévas M, Germain J, Languille L, Comont T, Lapeyre-Mestre M, Payrastre B, Beyne-Rauzy O, Michel M, Godeau B, Adoue D, Moulis G; CARMEN investigators group.

J Thromb Haemost. 2018 Sep;16(9):1830-1842. doi: 10.1111/jth.14227. Epub 2018 Aug 12.

PMID:
29978544
7.

Prospective evaluation of the effect of deferasirox on hematologic response in transfusion-dependent patients with low-risk MDS and iron overload.

Rose C, Lenoir C, Gyan E, Hacini M, Amé S, Corront B, Beyne-Rauzy O, Adiko D, Loppinet E, Ali-Ammar N, Laribi K, Wattel E, Dreyfus F, Roué CS, Cheze S.

Eur J Haematol. 2018 May 2. doi: 10.1111/ejh.13088. [Epub ahead of print]

PMID:
29719933
8.

Azacitidine improves outcome in higher-risk MDS patients with chromosome 7 abnormalities: a retrospective comparison of GESMD and GFM registries.

Díez-Campelo M, Lorenzo JI, Itzykson R, Rojas SM, Berthon C, Luño E, Beyne-Rauzy O, Perez-Oteyza J, Vey N, Bargay J, Park S, Cedena T, Bordessoule D, Muñoz JA, Gyan E, Such E, Visanica S, López-Cadenas F, de Botton S, Hernández-Rivas JM, Ame S, Stamatoullas A, Delaunay J, Salanoubat C, Isnard F, Guieze R, Pérez Guallar J, Badiella L, Sanz G, Cañizo C, Fenaux P.

Br J Haematol. 2018 May;181(3):350-359. doi: 10.1111/bjh.15190. Epub 2018 Apr 2.

PMID:
29611196
9.

The Impact of a Small Private Online Course as a New Approach to Teaching Oncology: Development and Evaluation.

Vaysse C, Chantalat E, Beyne-Rauzy O, Morineau L, Despas F, Bachaud JM, Caunes N, Poublanc M, Serrano E, Bugat R, Rougé Bugat ME, Fize AL.

JMIR Med Educ. 2018 Mar 5;4(1):e6. doi: 10.2196/mededu.9185.

10.

Prognostic impact of a suboptimal number of analyzed metaphases in normal karyotype lower-risk MDS.

de Swart L, Smith A, Haase D, Fenaux P, Symeonidis A, Cermak J, Sanz G, Stauder R, Mittelman M, Hellström-Lindberg E, Malcovati L, Langemeijer S, Skov-Holm M, Mądry K, Germing U, Almeida AM, Tatic A, Savic A, Šimec NG, van Marrewijk C, Guerci-Bresler A, Sanhes L, Luño E, Culligan D, Beyne-Rauzy O, Burgstaller S, Blijlevens N, Bowen D, de Witte T.

Leuk Res. 2018 Apr;67:21-26. doi: 10.1016/j.leukres.2018.01.022. Epub 2018 Jan 31.

11.

Pretreatment with standard-dose intravenous methylprednisolone does not improve outcomes in newly diagnosed immune thrombocytopenia (ITP).

Essilini A, Comont T, Germain J, Brun N, Dingremont C, Castel B, Arista S, Madaule S, Sailler L, Lapeyre-Mestre M, Beyne-Rauzy O, Godeau B, Adoue D, Moulis G; CARMEN investigators group.

Eur J Haematol. 2018 May;100(5):412-418. doi: 10.1111/ejh.13032. Epub 2018 Mar 12.

PMID:
29360249
12.

Sotatercept with long-term extension for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes: a phase 2, dose-ranging trial.

Komrokji R, Garcia-Manero G, Ades L, Prebet T, Steensma DP, Jurcic JG, Sekeres MA, Berdeja J, Savona MR, Beyne-Rauzy O, Stamatoullas A, DeZern AE, Delaunay J, Borthakur G, Rifkin R, Boyd TE, Laadem A, Vo B, Zhang J, Puccio-Pick M, Attie KM, Fenaux P, List AF.

Lancet Haematol. 2018 Feb;5(2):e63-e72. doi: 10.1016/S2352-3026(18)30002-4. Epub 2018 Jan 10.

PMID:
29331635
13.

Re: Severe Primary Autoimmune Thrombocytopenia (ITP) in Pregnancy: a national cohort study Primary immune thrombocytopenia management during pregnancy. A French study.

Comont T, Moulis G, Delavigne K, Cougoul P, Parant O, Guyard-Boileau B, Derumeaux H, Adoue D, Beyne-Rauzy O.

BJOG. 2018 Apr;125(5):629-630. doi: 10.1111/1471-0528.14856. Epub 2017 Sep 20. No abstract available.

14.

Clinical characteristics and outcomes according to age in lenalidomide-treated patients with RBC transfusion-dependent lower-risk MDS and del(5q).

Fenaux P, Giagounidis A, Selleslag D, Beyne-Rauzy O, Mittelman M, Muus P, Nimer SD, Hellström-Lindberg E, Powell BL, Guerci-Bresler A, Sekeres MA, Deeg HJ, Del Cañizo C, Greenberg PL, Shammo JM, Skikne B, Yu X, List AF.

J Hematol Oncol. 2017 Jun 26;10(1):131. doi: 10.1186/s13045-017-0491-2.

15.

Bone marrow involvement in systemic lupus erythematosus.

Chalayer E, Costedoat-Chalumeau N, Beyne-Rauzy O, Ninet J, Durupt S, Tebib J, Asli B, Lambotte O, Ffrench M, Vasselon C, Cathébras P.

QJM. 2017 Nov 1;110(11):701-711. doi: 10.1093/qjmed/hcx102.

PMID:
28525589
16.

Validation of response assessment according to international consortium for MDS/MPN criteria in chronic myelomonocytic leukemia treated with hypomethylating agents.

Duchmann M, Braun T, Micol JB, Platzbecker U, Park S, Pilorge S, Beyne-Rauzy O, Vey N, Sébert M, Gruson B, Dumas PY, Guieze R, Chretien ML, Laribi K, Chait Y, Legros L, Sahnes L, Hirsch P, Salanoubat C, Solary E, Fenaux P, Itzykson R.

Blood Cancer J. 2017 May 12;7(5):e562. doi: 10.1038/bcj.2017.41. No abstract available.

17.

Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents.

Park S, Hamel JF, Toma A, Kelaidi C, Thépot S, Campelo MD, Santini V, Sekeres MA, Balleari E, Kaivers J, Sapena R, Götze K, Müller-Thomas C, Beyne-Rauzy O, Stamatoullas A, Kotsianidis I, Komrokji R, Steensma DP, Fensterl J, Roboz GJ, Bernal T, Ramos F, Calabuig M, Guerci-Bresler A, Bordessoule D, Cony-Makhoul P, Cheze S, Wattel E, Rose C, Vey N, Gioia D, Ferrero D, Gaidano G, Cametti G, Pane F, Sanna A, Germing U, Sanz GF, Dreyfus F, Fenaux P.

J Clin Oncol. 2017 May 10;35(14):1591-1597. doi: 10.1200/JCO.2016.71.3271. Epub 2017 Mar 28.

PMID:
28350519
18.

Newly diagnosed immune thrombocytopenia adults: Clinical epidemiology, exposure to treatments, and evolution. Results of the CARMEN multicenter prospective cohort.

Moulis G, Germain J, Comont T, Brun N, Dingremont C, Castel B, Arista S, Sailler L, Lapeyre-Mestre M, Beyne-Rauzy O, Godeau B, Adoue D; CARMEN Investigators Group.

Am J Hematol. 2017 Jun;92(6):493-500. doi: 10.1002/ajh.24702. Epub 2017 Mar 20.

19.

Midostaurin in Advanced Systemic Mastocytosis.

Chandesris MO, Damaj G, Canioni D, Brouzes C, Lhermitte L, Hanssens K, Frenzel L, Cherquaoui Z, Durieu I, Durupt S, Gyan E, Beyne-Rauzy O, Launay D, Faure C, Hamidou M, Besnard S, Diouf M, Schiffmann A, Niault M, Jeandel PY, Ranta D, Gressin R, Chantepie S, Barete S, Dubreuil P, Bourget P, Lortholary O, Hermine O; CEREMAST Study Group.

N Engl J Med. 2016 Jun 30;374(26):2605-7. doi: 10.1056/NEJMc1515403. No abstract available.

PMID:
27355555
20.

A randomized phase II trial of azacitidine +/- epoetin-β in lower-risk myelodysplastic syndromes resistant to erythropoietic stimulating agents.

Thépot S, Ben Abdelali R, Chevret S, Renneville A, Beyne-Rauzy O, Prébet T, Park S, Stamatoullas A, Guerci-Bresler A, Cheze S, Tertian G, Choufi B, Legros L, Bastié JN, Delaunay J, Chaury MP, Sanhes L, Wattel E, Dreyfus F, Vey N, Chermat F, Preudhomme C, Fenaux P, Gardin C; Groupe Francophone des Myélodysplasies (GFM).

Haematologica. 2016 Aug;101(8):918-25. doi: 10.3324/haematol.2015.140988. Epub 2016 May 26.

21.

Are somatic mutations predictive of response to erythropoiesis stimulating agents in lower risk myelodysplastic syndromes?

Kosmider O, Passet M, Santini V, Platzbecker U, Andrieu V, Zini G, Beyne-Rauzy O, Guerci A, Masala E, Balleari E, Bulycheva E, Dreyfus F, Fenaux P, Fontenay M, Park S; GFM, FISM AND D-MDS.

Haematologica. 2016 Jul;101(7):e280-3. doi: 10.3324/haematol.2016.142695. Epub 2016 Apr 7. No abstract available.

22.

Validation of immune thrombocytopenia diagnosis code in the French hospital electronic database.

Moulis G, Germain J, Adoue D, Beyne-Rauzy O, Derumeaux H, Sailler L, Lapeyre-Mestre M.

Eur J Intern Med. 2016 Jul;32:e21-2. doi: 10.1016/j.ejim.2016.02.021. Epub 2016 Mar 21. No abstract available.

PMID:
27012473
23.

Myelodysplastic syndromes with single neutropenia or thrombocytopenia are rarely refractory cytopenias with unilineage dysplasia by World Health Organization 2008 criteria and have favourable prognosis.

Gyan E, Andrieu V, Sanna A, Caille A, Schemenau J, Sudaka I, Siguret V, Malet M, Park S, Bordessoule D, Mairesse J, Gelsi-Boyer V, Cheze S, Beyne-Rauzy O, Sébert M, Sapena R, Zerazhi H, Legros L, Guerci-Bresler A, Amé SN, Germing U, Santini V, Salvi F, Gioia D, Lunghi M, Dreyfus F, Fenaux P; Groupe Francophone des Myélodysplasies, Fondazione Italiana per le Sindromi Mielodisplastiche (FISMonlus), and Düsseldorf MDS Registry.

Br J Haematol. 2016 Dec;175(5):975-979. doi: 10.1111/bjh.13902. Epub 2016 Jan 15. No abstract available.

PMID:
26773632
24.

Effect of lenalidomide treatment on clonal architecture of myelodysplastic syndromes without 5q deletion.

Chesnais V, Renneville A, Toma A, Lambert J, Passet M, Dumont F, Chevret S, Lejeune J, Raimbault A, Stamatoullas A, Rose C, Beyne-Rauzy O, Delaunay J, Solary E, Fenaux P, Dreyfus F, Preudhomme C, Kosmider O, Fontenay M; Groupe Francophone des Myélodysplasies.

Blood. 2016 Feb 11;127(6):749-60. doi: 10.1182/blood-2015-04-640128. Epub 2015 Dec 1.

25.

Lenalidomide with or without erythropoietin in transfusion-dependent erythropoiesis-stimulating agent-refractory lower-risk MDS without 5q deletion.

Toma A, Kosmider O, Chevret S, Delaunay J, Stamatoullas A, Rose C, Beyne-Rauzy O, Banos A, Guerci-Bresler A, Wickenhauser S, Caillot D, Laribi K, De Renzis B, Bordessoule D, Gardin C, Slama B, Sanhes L, Gruson B, Cony-Makhoul P, Chouffi B, Salanoubat C, Benramdane R, Legros L, Wattel E, Tertian G, Bouabdallah K, Guilhot F, Taksin AL, Cheze S, Maloum K, Nimuboma S, Soussain C, Isnard F, Gyan E, Petit R, Lejeune J, Sardnal V, Renneville A, Preudhomme C, Fontenay M, Fenaux P, Dreyfus F.

Leukemia. 2016 Apr;30(4):897-905. doi: 10.1038/leu.2015.296. Epub 2015 Oct 26.

26.

Prognostic value of self-reported fatigue on overall survival in patients with myelodysplastic syndromes: a multicentre, prospective, observational, cohort study.

Efficace F, Gaidano G, Breccia M, Voso MT, Cottone F, Angelucci E, Caocci G, Stauder R, Selleslag D, Sprangers M, Platzbecker U, Ricco A, Sanpaolo G, Beyne-Rauzy O, Buccisano F, Palumbo GA, Bowen D, Nguyen K, Niscola P, Vignetti M, Mandelli F.

Lancet Oncol. 2015 Nov;16(15):1506-1514. doi: 10.1016/S1470-2045(15)00206-5. Epub 2015 Sep 21.

PMID:
26404501
27.

Ribavirin for Chronic Hepatitis Prevention among Patients with Hematologic Malignancies.

Tavitian S, Peron JM, Huguet F, Kamar N, Abravanel F, Beyne-Rauzy O, Oberic L, Faguer S, Alric L, Roussel M, Gaudin C, Ysebaert L, Huynh A, Recher C.

Emerg Infect Dis. 2015 Aug;21(8):1466-9. doi: 10.3201/eid2108.150199.

28.

FDG-PET/CT findings in systemic mastocytosis: a French multicentre study.

Djelbani-Ahmed S, Chandesris MO, Mekinian A, Canioni D, Brouzes C, Hanssens K, Pop G, Durieu I, Durupt S, Grosbois B, Besnard S, Tournilhac O, Beyne-Rauzy O, Agapé P, Delmer A, Ranta D, Jeandel PY, Georgin-Lavialle S, Frenzel L, Damaj G, Eder V, Lortholary O, Hermine O, Fain O, Soussan M.

Eur J Nucl Med Mol Imaging. 2015 Dec;42(13):2013-20. doi: 10.1007/s00259-015-3117-3. Epub 2015 Jul 5.

PMID:
26140850
29.

Accuracy of physician assessment of treatment preferences and health status in elderly patients with higher-risk myelodysplastic syndromes.

Caocci G, Voso MT, Angelucci E, Stauder R, Cottone F, Abel G, Nguyen K, Platzbecker U, Beyne-Rauzy O, Gaidano G, Invernizzi R, Molica S, Criscuolo M, Breccia M, Lübbert M, Sanpaolo G, Buccisano F, Ricco A, Palumbo GA, Niscola P, Zhang H, Fenu S, La Nasa G, Mandelli F, Efficace F.

Leuk Res. 2015 Aug;39(8):859-65. doi: 10.1016/j.leukres.2015.05.012. Epub 2015 Jun 12.

PMID:
26120100
30.

Validation of the revised international prognostic scoring system (IPSS-R) in patients with lower-risk myelodysplastic syndromes: a report from the prospective European LeukaemiaNet MDS (EUMDS) registry.

de Swart L, Smith A, Johnston TW, Haase D, Droste J, Fenaux P, Symeonidis A, Sanz G, Hellström-Lindberg E, Cermák J, Germing U, Stauder R, Georgescu O, MacKenzie M, Malcovati L, Holm MS, Almeida AM, Mądry K, Slama B, Guerci-Bresler A, Sanhes L, Beyne-Rauzy O, Luño E, Bowen D, de Witte T.

Br J Haematol. 2015 Aug;170(3):372-83. doi: 10.1111/bjh.13450. Epub 2015 Apr 24.

PMID:
25907546
31.

A phase I/II trial of Erlotinib in higher risk myelodysplastic syndromes and acute myeloid leukemia after azacitidine failure.

Thepot S, Boehrer S, Seegers V, Prebet T, Beyne-Rauzy O, Wattel E, Delaunay J, Raffoux E, Hunault M, Jourdan E, Chermat F, Sebert M, Kroemer G, Fenaux P, Adès L; Groupe Francophone des Myelodysplasies (GFM).

Leuk Res. 2014 Dec;38(12):1430-4. doi: 10.1016/j.leukres.2014.09.014. Epub 2014 Oct 7.

PMID:
25449687
32.

Prevalence, severity and correlates of fatigue in newly diagnosed patients with myelodysplastic syndromes.

Efficace F, Gaidano G, Breccia M, Criscuolo M, Cottone F, Caocci G, Bowen D, Lübbert M, Angelucci E, Stauder R, Selleslag D, Platzbecker U, Sanpaolo G, Jonasova A, Buccisano F, Specchia G, Palumbo GA, Niscola P, Wan C, Zhang H, Fenu S, Klimek V, Beyne-Rauzy O, Nguyen K, Mandelli F.

Br J Haematol. 2015 Feb;168(3):361-70. doi: 10.1111/bjh.13138. Epub 2014 Oct 1.

PMID:
25272332
33.

Intensive chemotherapy, azacitidine, or supportive care in older acute myeloid leukemia patients: an analysis from a regional healthcare network.

Bories P, Bertoli S, Bérard E, Laurent J, Duchayne E, Sarry A, Delabesse E, Beyne-Rauzy O, Huguet F, Récher C.

Am J Hematol. 2014 Dec;89(12):E244-52. doi: 10.1002/ajh.23848. Epub 2014 Oct 20.

34.

Outcomes in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with isolated deletion 5q treated with lenalidomide: a subset analysis from the MDS-004 study.

Giagounidis A, Mufti GJ, Mittelman M, Sanz G, Platzbecker U, Muus P, Selleslag D, Beyne-Rauzy O, te Boekhorst P, del Cañizo C, Guerci-Bresler A, Nilsson L, Lübbert M, Quesnel B, Ganser A, Bowen D, Schlegelberger B, Göhring G, Fu T, Benettaib B, Hellström-Lindberg E, Fenaux P.

Eur J Haematol. 2014 Nov;93(5):429-38. doi: 10.1111/ejh.12380. Epub 2014 Jun 9.

35.

Prognostic impact of JAK2V617F mutation in myelodysplatic syndromes: A matched case control study.

de Renzis B, Mansat-De Mas V, Wattel E, Beyne-Rauzy O, Knoops L, Cabrespine A, Azgui Z, Ades L, Kiladjian JJ, Fenaux P; Groupe Francophone des Myelodysplasies (GFM), French Intergroup of Myeloproliferative disorders (FIM).

Leuk Res Rep. 2013 Aug 30;2(2):64-6. doi: 10.1016/j.lrr.2013.06.003. eCollection 2013.

36.

Can the revised IPSS predict response to erythropoietic-stimulating agents in patients with classical IPSS low or intermediate-1 MDS?

Santini V, Schemenau J, Levis A, Balleari E, Sapena R, Adès L, Guerci A, Beyne-Rauzy O, Gourin MP, Cheze S, Stamatoullas A, Sanna A, Gioia D, Cametti G, Ferrero D, Raffoux E, Rose C, Poloni A, Prebet T, Legros L, Natarajan-Amé S, Fenaux P, Germing U, Dreyfus F, Park S.

Blood. 2013 Sep 26;122(13):2286-8. doi: 10.1182/blood-2013-07-512442. No abstract available.

37.

Combination of vorinostat and low dose cytarabine for patients with azacitidine-refractory/relapsed high risk myelodysplastic syndromes.

Prebet T, Braun T, Beyne-Rauzy O, Dreyfus F, Stammatoullas A, Wattel E, Ame S, Raffoux E, Delaunay J, Charbonnier A, Adès L, Fenaux P, Vey N.

Leuk Res. 2014 Jan;38(1):29-33. doi: 10.1016/j.leukres.2013.07.023. Epub 2013 Aug 13.

PMID:
23953882
38.

Prognostic score including gene mutations in chronic myelomonocytic leukemia.

Itzykson R, Kosmider O, Renneville A, Gelsi-Boyer V, Meggendorfer M, Morabito M, Berthon C, Adès L, Fenaux P, Beyne-Rauzy O, Vey N, Braun T, Haferlach T, Dreyfus F, Cross NC, Preudhomme C, Bernard OA, Fontenay M, Vainchenker W, Schnittger S, Birnbaum D, Droin N, Solary E.

J Clin Oncol. 2013 Jul 1;31(19):2428-36. doi: 10.1200/JCO.2012.47.3314. Epub 2013 May 20.

PMID:
23690417
39.

Cardiac iron overload assessed by T2* magnetic resonance imaging and cardiac function in regularly transfused myelodysplastic syndrome patients.

Pascal L, Beyne-Rauzy O, Brechignac S, Marechaux S, Vassilieff D, Ernst O, Berthon C, Gyan E, Gourin MP, Dreyfus F, Fenaux P, Rose C.

Br J Haematol. 2013 Aug;162(3):413-5. doi: 10.1111/bjh.12368. Epub 2013 May 9. No abstract available.

PMID:
23656172
40.

Impact of an oncogeriatric consulting team on therapeutic decision-making.

Rougé-Bugat ME, Gérard S, Balardy L, Beyne-Rauzy O, Boussier N, Perrin A, Oustric S, Vellas B, Nourhashémi F.

J Nutr Health Aging. 2013;17(5):473-8. doi: 10.1007/s12603-012-0435-z.

PMID:
23636550
41.

Long-term outcome of anemic lower-risk myelodysplastic syndromes without 5q deletion refractory to or relapsing after erythropoiesis-stimulating agents.

Kelaidi C, Park S, Sapena R, Beyne-Rauzy O, Coiteux V, Vey N, Stamatoullas A, Choufi B, Delaunay J, Gourin MP, Cheze S, Ravoet C, Ferrant A, Escoffre-Barbe M, Aljassem L, Raffoux E, Itzykson R, Adès L, Dreyfus F, Fenaux P.

Leukemia. 2013 Jun;27(6):1283-90. doi: 10.1038/leu.2013.16. Epub 2013 Jan 16.

PMID:
23370672
42.

High response rate and improved exercise capacity and quality of life with a new regimen of darbepoetin alfa with or without filgrastim in lower-risk myelodysplastic syndromes: a phase II study by the GFM.

Kelaidi C, Beyne-Rauzy O, Braun T, Sapena R, Cougoul P, Adès L, Pillard F, Lamberto C, Charniot JC, Guerci A, Choufi B, Stamatoullas A, Slama B, De Renzis B, Ame S, Damaj G, Boyer F, Chaury MP, Legros L, Cheze S, Testu A, Gyan E, Béné MC, Rose C, Dreyfus F, Fenaux P.

Ann Hematol. 2013 May;92(5):621-31. doi: 10.1007/s00277-013-1686-4. Epub 2013 Jan 29. Erratum in: Ann Hematol. 2013 May;92(5):633. Lambert, Christine [corrected to Lamberto, C].

PMID:
23358617
43.

[Myelodysplastic syndromes].

Beyne-Rauzy O.

Rev Med Interne. 2012 Dec;33 Suppl 2:A21-3. doi: 10.1016/j.revmed.2012.09.015. Epub 2012 Oct 24. French. No abstract available.

PMID:
23103124
44.

Outcome of acute myeloid leukaemia following myelodysplastic syndrome after azacitidine treatment failure.

Prébet T, Gore SD, Thépot S, Esterni B, Quesnel B, Beyne Rauzy O, Dreyfus F, Gardin C, Fenaux P, Vey N.

Br J Haematol. 2012 Jun;157(6):764-6. doi: 10.1111/j.1365-2141.2012.09076.x. Epub 2012 Mar 6. No abstract available.

45.

Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes.

Damm F, Kosmider O, Gelsi-Boyer V, Renneville A, Carbuccia N, Hidalgo-Curtis C, Della Valle V, Couronné L, Scourzic L, Chesnais V, Guerci-Bresler A, Slama B, Beyne-Rauzy O, Schmidt-Tanguy A, Stamatoullas-Bastard A, Dreyfus F, Prébet T, de Botton S, Vey N, Morgan MA, Cross NC, Preudhomme C, Birnbaum D, Bernard OA, Fontenay M; Groupe Francophone des Myélodysplasies.

Blood. 2012 Apr 5;119(14):3211-8. doi: 10.1182/blood-2011-12-400994. Epub 2012 Feb 17.

46.

Diffuse pulmonary uptake on FDG-PET with normal CT diagnosed as intravascular large B-cell lymphoma: a case report and a discussion of the causes of diffuse FDG uptake in the lungs.

Wagner T, Brechemier D, Dugert E, Le Guellec S, Julian A, Hitzel A, Beyne-Rauzy O.

Cancer Imaging. 2012 Jan 23;12:7-12. doi: 10.1102/1470-7330.2012.0002.

47.

Does addition of erythropoiesis stimulating agents improve the outcome of higher-risk myelodysplastic syndromes treated with azacitidine?

Itzykson R, Thépot S, Beyne-Rauzy O, Ame S, Isnard F, Dreyfus F, Salanoubat C, Taksin AL, Chelgoum Y, Berthon C, Malfuson JV, Legros L, Vey N, Turlure P, Gardin C, Boehrer S, Ades L, Fenaux P; Groupe Francophone des Myelodysplasies (GFM).

Leuk Res. 2012 Apr;36(4):397-400. doi: 10.1016/j.leukres.2011.11.019. Epub 2011 Dec 15.

PMID:
22177456
48.

SF3B1 mutations in myelodysplastic syndromes: clinical associations and prognostic implications.

Damm F, Thol F, Kosmider O, Kade S, Löffeld P, Dreyfus F, Stamatoullas-Bastard A, Tanguy-Schmidt A, Beyne-Rauzy O, de Botton S, Guerci-Bresler A, Göhring G, Schlegelberger B, Ganser A, Bernard OA, Fontenay M, Heuser M.

Leukemia. 2012 May;26(5):1137-40. doi: 10.1038/leu.2011.321. Epub 2011 Nov 8. No abstract available.

PMID:
22064355
49.

[Antiphospholipid antibodies and the risk of thrombosis: a comparative survey between chronic immune thrombocytopenia and primary antiphospholipid syndrome].

Moulis G, Delavigne K, Huguet F, Fortenfant F, Beyne-Rauzy O, Adoue D.

Rev Med Interne. 2011 Dec;32(12):724-9. doi: 10.1016/j.revmed.2011.07.014. Epub 2011 Aug 23. French.

PMID:
21864953
50.

Ferritin level at diagnosis is not correlated with poorer survival in non RBC transfusion dependent lower risk de novo MDS.

Park S, Sapena R, Kelaidi C, Vassilieff D, Bordessoule D, Stamatoullas A, Cheze S, Beyne-Rauzy O, Vey N, Rose C, Guerci A, Natarajan-Amé S, Tertian G, Slama B, Fenaux P, Dreyfus F.

Leuk Res. 2011 Nov;35(11):1530-3. doi: 10.1016/j.leukres.2011.07.007. Epub 2011 Jul 30.

PMID:
21803419

Supplemental Content

Loading ...
Support Center